Last reviewed · How we verify
low intensity warfarin
Low-intensity warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) at reduced doses to provide anticoagulation with a lower bleeding risk profile.
Low-intensity warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) at reduced doses to provide anticoagulation with a lower bleeding risk profile. Used for Thromboprophylaxis in patients at risk for venous thromboembolism, Stroke prevention in atrial fibrillation (at reduced intensity).
At a glance
| Generic name | low intensity warfarin |
|---|---|
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Vitamin K antagonist (coumarin anticoagulant) |
| Target | Vitamin K epoxide reductase complex 1 (VKORC1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Warfarin is a coumarin anticoagulant that antagonizes vitamin K, reducing the synthesis of vitamin K-dependent coagulation factors. Low-intensity dosing aims to achieve a lower International Normalized Ratio (INR, typically 1.5–2.0) compared to standard warfarin therapy (INR 2.0–3.0), potentially reducing hemorrhagic complications while maintaining thromboprophylactic efficacy in select patient populations.
Approved indications
- Thromboprophylaxis in patients at risk for venous thromboembolism
- Stroke prevention in atrial fibrillation (at reduced intensity)
Common side effects
- Bleeding (minor)
- Bleeding (major)
- Warfarin necrosis
- INR elevation/over-anticoagulation
Key clinical trials
- Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
- Trial of Low-intensity Anticoagulation to Reduce GI or Other Bleeding Complications With Equivalent Therapeutic Efficacy in HeartMate 3 LVAD Patients (PHASE4)
- MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1) (NA)
- D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement
- The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients (PHASE4)
- The Effect and Safety of Different Intensity Anticoagulation Therapy in Elderly Patients With Non-valvular Atrial Fibrillation (PHASE4)
- Warfarin and Antiplatelet Vascular Evaluation (PHASE3)
- Access II - Trial of Warfarin to Prevent Malfunction of Haemodialysis Catheters (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: